Thursday, April 7, 2011
Teva Pharmaceutical Industries Ltd., of Jerusalem, Israel, and OncoGenex Pharmaceuticals Inc., of Bothell, Wash., presented preclinical data on their investigational compound custirsen (OGX-011/TV-1011), which is being investigated in Phase III studies in castrate-resistant prostate cancer. Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types and in response to many cancer treatments. The companies also presented data showing an inhibitory effect of custirsen on heat-shock protein 90 (HSP90) in prostate cancer cells. Inhibition of HSP90 is being investigated as a strategy to treat prostate cancer, and the addition of custirsen may enhance the activity of HSP90 inhibitors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.